초록 ▼

The present invention relates to methods, compositions, devices and kits for the prevention and treatment of prostate disorders in mammals, including, but not limited to, benign prostatic hypertrophy, carcinoma of the prostate, prostadynia, prostatitis, and chronic prostatitis. The present invention

The present invention relates to methods, compositions, devices and kits for the prevention and treatment of prostate disorders in mammals, including, but not limited to, benign prostatic hypertrophy, carcinoma of the prostate, prostadynia, prostatitis, and chronic prostatitis. The present invention provides methods for preventing and treating prostate disorders in mammals by administration of a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal. The present invention also provides devices for administering a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal.

대표청구항 ▼

1. A method of treating benign prostatic hypertrophy in mammals, comprising: topical administration, to the urethra or the glans penis, of a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of prostaglandins, interferons, prostaglandin dehydrog

1. A method of treating benign prostatic hypertrophy in mammals, comprising: topical administration, to the urethra or the glans penis, of a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of prostaglandins, interferons, prostaglandin dehydrogenase inhibitors, and phosphodiesterase inhibitors. 2. The method of claim 1, wherein the therapeutic compound is a prostaglandin and an interferon. 3. The method of claim 1, wherein the prostaglandin is selected from PGE-1, PGE-2, PGE-3, misoprostol, misoprostanoic acid, PGA-1, PGA-2, PGJ-2, Δ12-PGJ-2, 15-deoxy-Δ12,14-PGJ-2, PGD-2, and 15-deoxy-Δ12,14-PGD-2. 4. The method of claim 1, wherein the interferon is selected from interferon alpha-2a, interferon alpha-2b, and interferon gamma-1b. 5. The method of claim 1, wherein the phosphodiesterase inhibitor is selected from caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and sildenafil. 6. The method of claim 1, wherein the therapeutic compound is a prostaglandin E and a prostaglandin dehydrogenase inhibitor. 7. The method of claim 1, wherein the therapeutic compound is administered directly to the prostatic urethra by way of a catheter placed in the urethra. 8. The method of claim 1, wherein the therapeutic compound is administered directly to the prostatic urethra by way of a medicated ring or a drug reservoir means. 9. The method of claim 1, wherein the therapeutic compound is administered directly to the meatus or the glans penis in the form of a suppository, solution, gel, or cream. 10. A composition for administration to the urethra, meatus or glans penis for the treatment of benign prostatic hypertrophy, comprising: a therapeutically effective amount of a prostaglandin E compound and an interferon. 11. A composition for administration to the urethra, meatus or glans penis for the treatment of benign prostatic hypertrophy, comprising: a therapeutically effective amount of a prostaglandin E and a prostaglandin dehydrogenase inhibitor. 12. A device for the treatment of benign prostatic hypertrophy that administers a therapeutic compound to the prostatic urethra of a mammal, comprising: (a) a drug reservoir means, comprising: a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of prostaglandins, interferons, prostaglandin dehydrogenase inhibitors, and phosphodiesterase inhibitors; and, (b) a central tubular means allowing uninterrupted flow of urine from the bladder to the penile urethra. 13. The device of claim 12, wherein the drug reservoir means is a medicated ring comprising: an outer ring of material that is in contact with the prostatic urethra and the therapeutic compound. 14. The device of claim 13, wherein the outer ring comprises a time-release material selected from hydrogels, high melting triglycerides, polyethylene glycols, polyethylene oxides, methyl palmitate, tripalmitin and an osmotic pillow. 15. The method of claim 1, wherein the topical administration is to the glans penis. 16. The method of claim 15, wherein the therapeutic compound is a prostaglandin and an interferon. 17. The method of claim 15, wherein the prostaglandin is selected from PGE-1, PGE-2, PGE-3, misoprostol, misoprostanoic acid, PGA-1, PGA-2, PGJ-2, Δ12-PGJ-2, 15-deoxy-Δ12,14-PGJ-2, PGD-2, and 15-deoxy-Δ12,14-PGD-2. 18. The method of claim 15, wherein the interferon is selected from interferon alpha-2a, interferon alpha-2b and interferon gamma-1b. 19. The method of claim 15, wherein the phosphodiesterase inhibitor is selected from caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and sildenafil.